Received grant in 2017
DCCC has funded 100,000 DKK to the project.
The purpose of the collaboration is to issue a comprehensive clinical protocol for implementation and validation of personal medicine (PM) in Danish cancer departments.
The infrastructure surrounding DMCG.dk, clinical databases, biobanks and bioinformatics will create the foundation of a two-phase program focusing on cancer diseases with no standard therapy. The idea is that the cancer tissue at time of recurrence will be isolated and treated with whole genome sequencing according to the Danish strategy for PM. By doing so we take advantage of the new infrastructures associated with the Danish Genome Center for individual predictive molecular resistance based on algorithms and possible choice of therapy.
Project stakeholders
- Henrik Ditzel, Department of Molecular Medicine – Cancer and Inflammation Research, University of Southern Denmark. Primary contact, mail: hditzel@health.sdu.dk
- Nils Brünner, Department of Drug Design and Pharmacology, University of Copenhagen